318 related articles for article (PubMed ID: 15112270)
1. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
2. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
4. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
5. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy.
Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ
Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
Burns DM; Crawford DH
Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
[TBL] [Abstract][Full Text] [Related]
7. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus and Hodgkin's lymphoma.
Andersson J
Herpes; 2006 May; 13(1):12-6. PubMed ID: 16732997
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
10. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Meijer E; Cornelissen JJ
Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
[TBL] [Abstract][Full Text] [Related]
12. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
Wagner HJ; Sili U; Gahn B; Vigouroux S; Huls MH; Xie W; Vignali D; Brenner MK; Heslop HE; Rooney CM
Cytotherapy; 2003; 5(3):231-40. PubMed ID: 12850791
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Hodgkin's disease.
Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE
Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071
[TBL] [Abstract][Full Text] [Related]
15. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
[TBL] [Abstract][Full Text] [Related]
16. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.
Papadopoulos EB; Ladanyi M; Emanuel D; Mackinnon S; Boulad F; Carabasi MH; Castro-Malaspina H; Childs BH; Gillio AP; Small TN
N Engl J Med; 1994 Apr; 330(17):1185-91. PubMed ID: 8093146
[TBL] [Abstract][Full Text] [Related]
17. Two cases of chronic active Epstein-Barr virus infection in which EBV-specific cytotoxic T lymphocyte was induced after allogeneic bone marrow transplantation.
Miyamura T; Chayama K; Wada T; Yamaguchi K; Yamashita N; Ishida T; Washio K; Morishita N; Manki A; Oda M; Morishima T
Pediatr Transplant; 2008 Aug; 12(5):588-92. PubMed ID: 18266798
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
Clave E; Agbalika F; Bajzik V; Peffault de Latour R; Trillard M; Rabian C; Scieux C; Devergie A; Socié G; Ribaud P; Adès L; Ferry C; Gluckman E; Charron D; Esperou H; Toubert A; Moins-Teisserenc H
Transplantation; 2004 Jan; 77(1):76-84. PubMed ID: 14724439
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection.
Fujii N; Takenaka K; Hiraki A; Maeda Y; Ikeda K; Shinagawa K; Ashiba A; Munemasa M; Sunami K; Hiramatsu Y; Ishimaru F; Niiya K; Yoshino T; Harada M
Bone Marrow Transplant; 2000 Oct; 26(7):805-8. PubMed ID: 11042666
[TBL] [Abstract][Full Text] [Related]
20. [Adoptive immune therapy using EBV-specific CTL].
Kuzushima K; Morishima T
Nihon Rinsho; 1997 Feb; 55(2):473-8. PubMed ID: 9046843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]